Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for CSA-AKI Prevention
NCT05652179Completed
- Sponsor
- Yangzhou University
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine in acute kidney injury (AKI) (2 arms), sponsored by Yangzhou University. Primary endpoint: Incidence and severity of Cardiac Surgery-Associated Acute Kidney Injury. Started Jan 2023; status: completed.
02
Drugs
ropivacaine
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05652179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652179.